Cytopia, other shareholders call Progen general meeting 14:40, Wednesday, 28 January 2009
Sydney - Wednesday - Jan 28: (RWE Australian Business News) - Cytopia Ltd (ASX:CYT) has joined other Progen Pharmaceuticals Ltd (ASX:PGL) shareholders to call a Progen general meeting to elect a new board, pursue a merger and enable the first full share buyback offer to Progen shareholders. Key resolutions being put to Progen shareholders include: * offering shareholders the opportunity of having their shares bought back for $1.10 each; and * removal of the current board and replacement with three independent directors who would be elected on a declared platform of exploring a merger between Cytopia and Progen. To minimise cost and inconvenience, the meeting notice requests Progen to put the resolutions for consideration at the same time that a general meeting is held to consider the proposed merger between Progen and Avexa Ltd (ASX:AVX). "This will give shareholders much greater flexibility of choice and all resolutions can be dealt with in one forum," Cytopia said.
*****
"Cytopia is of the view that the Progen board appears to have lost the confidence of many investors after seemingly few achievements in the past few years," Cytopia said. "Three well-qualified and experienced directors", Mr Robert Collins, Dr Damian Pethica and Mr Tom Williams, are proposed for appointment to the board of Progen. These candidates bring "a strong mix of commercial and scientific skills necessary to drive corporate results for Progen" and are strongly supportive of a merger between Progen and Cytopia. To avoid any conflict of interest, no Cytopia representative has been nominated to the board. The candidates will be obliged to act in the best interests of Progen and the remaining Progen shareholders, and their intentions will have been openly communicated to all parties. This will allow for a fully informed decision to be taken by Progen shareholders at the meeting.
PGL Price at posting:
80.5¢ Sentiment: LT Buy Disclosure: Held